Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference



  Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013
                            Health Care Conference

PR Newswire

SAN DIEGO, May 7, 2013

SAN DIEGO, May 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:
HALO) will be presenting at the Bank of America Merrill Lynch 2013 Health Care
Conference in Las Vegas on Tuesday, May 14, 2013 at 1:40 p.m. PT/4:40 p.m. ET.
Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a
corporate overview.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's
corporate website at www.halozyme.com, and a recording will be made available
for 90 days following the event. To access the live webcast, please log on to
Halozyme's website approximately 15 minutes prior to the presentation to
register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing
and commercializing innovative products that advance patient care. With a
diversified portfolio of enzymes that target the extracellular matrix, the
Company's research focuses primarily on a family of human enzymes, known as
hyaluronidases, which increase the absorption and dispersion of biologics,
drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as
diabetes, oncology and dermatology that have significant unmet medical need.
The Company markets Hylenex® recombinant (hyaluronidase human injection) and
has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme
is headquartered in San Diego, CA.  For more information on how we are
innovating, please visit our corporate website at www.halozyme.com.

Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
ir@halozyme.com

Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
818-522-8411
Nurha.Hindi@hkstrategies.com

SOURCE Halozyme Therapeutics, Inc.

Website: http://www.halozyme.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement